Side Effects of Oral GLP-1 Tablets

GLP-1 tablets could transform the growing medicated weight loss market by offering a simpler, needle-free alternative to injections.

Until now, the most effective GLP-1 weight loss treatments have mainly been weekly injections, which can put some patients off due to needle anxiety, inconvenience or stigma.

Tablets remove this barrier, making treatment feel more familiar, discreet and easier to fit into daily life.

However, they should not be seen as a side-effect-free option. GLP-1 tablets are still prescription medicines that work on powerful appetite and digestive pathways.

Their main advantage is convenience, not necessarily fewer side effects.

The most common side effects of GLP-1 tablets are digestive symptoms.

These usually happen because GLP-1 medicines slow stomach emptying, reduce appetite and affect the way the gut communicates with the brain.

In clinical trial data, nausea, diarrhoea, constipation and vomiting are consistently among the most common side effects.

Side effects vary depending on the dose, the medicine used, individual tolerance and how quickly the dose is increased.

These figures are best understood as broad ranges across available GLP-1 tablet trial and prescribing data from Wegovy tablets and orforglipron, rather than exact predictions for every patient.

Side effects are most likely to happen when you first start GLP-1 tablets or increase your dose, as your body adjusts to the medicine’s effect on appetite and digestion.

Most side effects including digestive symptoms are mild to moderate, often improving after a few days or weeks.

Side effects may be worse if you eat large portions, eat too quickly, or have greasy, rich or heavy meals, as GLP-1 tablets make you feel fuller sooner.

Most people in clinical trials did not stop GLP-1 tablets because of side effects.

Across the available tablet data, around 7-8% of patients stopped treatment because of side effects, compared with around 3-6% of patients taking placebo.

Gastrointestinal side effects, such as nausea, vomiting, diarrhoea and abdominal discomfort, were the most common reasons for stopping treatment.

In simple terms, side effects are common, but only a relatively small proportion of patients stopped treatment completely because of them.

Most side effects are mild to moderate and tend to be worse when starting treatment, or when increasing the dose.

In clinical trial data for oral GLP-1 treatment, gastrointestinal side effects were common, but only a small percentage were classed as severe.

For example, prescribing data for one oral GLP-1 tablet reported that among patients who had gastrointestinal side effects, 60% were mild, 36% were moderate and 4% were severe.

Not necessarily. A tablet may feel more convenient and less invasive than an injection, but that does not automatically mean fewer side effects.

GLP-1 tablets still work on the same appetite and digestive pathways as injectable GLP-1 medicines. This means they can still cause nausea, vomiting, diarrhoea, constipation, indigestion and abdominal discomfort.

For oral semaglutide, prescribing information states that the types and frequency of common adverse reactions were similar to those seen with the injection.

The main advantage of tablets is convenience, not necessarily a milder side effect profile.

Serious side effects are uncommon, but patients should know what to look out for.

These can include:

• Pancreatitis
• Gallbladder problems, including gallstones and gallbladder inflammation
• Severe nausea, vomiting or diarrhoea
• Dehydration, which can lead to kidney problems
• Low blood sugar, especially in people taking insulin or sulfonylureas
• Allergic reactions
• Worsening diabetic eye disease in some patients with type 2 diabetes
• Increased heart rate
• Possible thyroid C-cell tumour risk, based mainly on animal data and class warnings

Pancreatitis means inflammation of the pancreas. It is rare with GLP-1 tablets, but it can be serious.

Symptoms may include severe abdominal pain that does not go away, pain spreading to the back, nausea or vomiting.

In available GLP-1 tablet clinical data, pancreatitis was uncommon, generally reported at well below 1% of patients or as a small number of cases per 100 patient-years.

Anyone who develops severe, persistent abdominal pain should stop treatment and seek urgent medical advice.

GLP-1 medicines may increase the risk of gallbladder problems, including gallstones and gallbladder inflammation.

Rapid weight loss itself can also increase the risk of gallstones, so the risk may come from the medicine, the weight loss, or both.

In available clinical trial data, gallstones were reported in roughly 1–2.5% of patients taking GLP-1 tablets, compared with around 0.7–1% on placebo. Gallbladder inflammation was reported less commonly, generally below 1%.

Symptoms of gallbladder problems can include pain in the upper right abdomen, pain after fatty meals, nausea, vomiting, fever, or yellowing of the skin or eyes.

Side effects can often be reduced by increasing the dose gradually, eating smaller meals and avoiding large, greasy or very rich foods.

It also helps to eat slowly, stop when comfortably full, drink enough fluids and avoid alcohol if it worsens nausea or reflux.

Patients should not increase the dose faster than prescribed. The gradual dose escalation is designed to help the body adjust and reduce the risk of stomach-related side effects.

GLP-1 tablets are a promising option for people who want weight loss treatment without injections. They may be more convenient, but they are not side-effect-free.

The most common side effects are nausea, diarrhoea, constipation, vomiting, indigestion and abdominal discomfort. Most are mild to moderate and often improve as the body adjusts, especially when the dose is increased gradually.

Serious side effects such as pancreatitis and gallbladder problems are uncommon, but patients should know the warning signs and seek medical advice if symptoms are severe, persistent or unusual.